Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1404&sort=principal_investigator
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=principal_investigator", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1424&sort=principal_investigator", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1405&sort=principal_investigator", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1403&sort=principal_investigator" }, "data": [ { "type": "Grant", "id": "15694", "attributes": { "award_id": "1R21AI187928-01A1", "title": "Introducing a novel computational framework for B-cell epitope prediction based on immune-induced selection signatures", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 32556, "first_name": "TIMOTHY A", "last_name": "GONDRE-LEWIS", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-07-01", "end_date": "2027-06-30", "award_amount": 406260, "principal_investigator": { "id": 32557, "first_name": "Qixin", "last_name": "He", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1139, "ror": "", "name": "PURDUE UNIVERSITY", "address": "", "city": "", "state": "IN", "zip": "", "country": "United States", "approved": true }, "abstract": "The accurate prediction of B-cell epitopes is essential for disease analysis, diagnostic tests, and vaccine design, yet it lags behind T-cell epitope prediction in precision. This is due to the complex nature of B-cell epitopes and the undersampling of mapped antibody-antigen structural data. To address this, we propose calculating the intensity of immune selection as an indicator of immunodominance because immune response-driven selection leaves detectable genetic signatures around common regions targeted by antibodies. Our preliminary data suggests that surface-adapted immune selection statistics recover common epitope sites in Sars-Cov-2 Spike, Influenza HA1, and malaria antigens. We have set out two primary aims to enhance B-cell epitope prediction. Aim 1: we plan to build a novel and comprehensive antigen database from 68 human pathogens, which maps 3D immune selection profiles onto the surfaces of antigens from common pathogens. Antigens will be selected from IEDB and their underlying population- level variation will be extracted from public genomic resources. Population genetics scores, such as Tajima's D and BetaScan, will be calculated on antigen surfaces. The resulting database will be deployed online for easy public access. Aim 2: we will develop a B-cell epitope predictor with two innovations. First, the training output comes from the normalized selection statistics of antigen surface instead of relying on antigen-antibody structures. Second, structural features for training inputs will be encoded through the Holographic-CNN model. The predictor's efficacy will then be compared against the state-of-the-art models using a distinct test set of experimentally resolved antigen-antibody structures. Upon completion, our predictor is expected to substantially elevate the predictive power of B-cell epitopes. Our antigen selection database will provide unparalleled new information for various research purposes of antigen evolution. These tools will be instrumental for reverse vaccinology, especially the design of epitope-based vaccines and the evaluation of the potential effectiveness of immunological interventions.", "keywords": [ "2019-nCoV", "3-Dimensional", "Address", "Allergens", "Antibodies", "Antigenic Variation", "Antigens", "Area Under Curve", "B-Lymphocyte Epitopes", "Benchmarking", "Bypass", "Classification", "Common Epitope", "Complex", "Data", "Databases", "Diagnostic tests", "Disease", "Effectiveness", "Epitope Mapping", "Epitopes", "Etiology", "Evaluation", "Evolution", "Exhibits", "Genomics", "Holography", "Immune", "Immune response", "Immunodominant Epitopes", "Infection", "Influenza", "Influenza A Virus H1N1 Subtype", "Label", "Learning", "Malaria", "Maps", "Measures", "Medical", "Methods", "Modeling", "Nature", "Neighborhoods", "Output", "Parasites", "Pattern", "Performance", "Population", "Population Genetics", "Property", "Proxy", "Publications", "Randomized", "Receiver Operating Characteristics", "Recombinant Proteins", "Research", "SARS-CoV-2 spike protein", "Site", "Structure", "Surface", "Surface Antigens", "T-Lymphocyte Epitopes", "Testing", "Training", "Vaccine Design", "Vaccines", "Validation", "Variant", "adaptive immune response", "candidate selection", "computer framework", "deep neural network", "design", "diagnostic assay", "genetic signature", "genome resource", "human pathogen", "immunological intervention", "improved", "innovation", "interest", "novel", "pathogen", "predictive modeling", "public database", "statistics", "stem", "tool", "vaccine candidate", "vaccinology" ], "approved": true } }, { "type": "Grant", "id": "15697", "attributes": { "award_id": "1R35GM158174-01", "title": "Multifunctionalized lipid derivatives", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of General Medical Sciences (NIGMS)" ], "program_reference_codes": [], "program_officials": [ { "id": 32560, "first_name": "KADIR", "last_name": "ASLAN", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-07-01", "end_date": "2030-06-30", "award_amount": 394214, "principal_investigator": { "id": 32561, "first_name": "Carsten", "last_name": "Schultz", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 765, "ror": "https://ror.org/009avj582", "name": "Oregon Health & Science University", "address": "", "city": "", "state": "OR", "zip": "", "country": "United States", "approved": true }, "abstract": "It is well understood how lipids are synthesized and metabolized in cells and that many lipids exhibit signalling functions to regulate cellular processes in a spatially and temporally defined way. The latter requires the build- up and turnover of lipid species in membranes either in a site-specific fashion or, alternatively, a directed form of lipid transport. This work aims to investigate the intracellular transfer of lipids from one membrane to another by several proteins that we discovered to be involved in lipid transport. In the previous funding period, we synthesized multifunctional lipid derivatives of five phosphoinositides and four common glycerophospholipids. These feature a photo-activatable protecting group (”cage”) to release the lipid derivative by light and a photo-crosslinking diazirine to covalently attach the lipid derivative to binding proteins. An alkyne group for click chemistry is useful for isolating lipid-protein conjugates or for determining the lipid location in cells by fluorescent tagging and microscopy. In published work, we identified specific lipid binding proteins for phosphatidylinositol 3,4,5-trisphosphate (PIP3), phosphatidylinositol 3,4-bisphosphate [PI(3,4)P2], and phosphatidylinositol (PI) via proteomic analysis. We then used siRNAs to block lipid transport and validated two hits that were required for transporting PIP3 and PI(3,4)P2: cytosolic MPP6 and transmembrane ATP11A. This R35 application proposes the continuation of work described in the application of R01 GM127631, namely the characterization of the lipid transport by the two above mentioned proteins (Project 1). This includes the purification and characterization of recombinant proteins and their functional mutants. We will use purified proteins to determine the 3D structure of MPP6 and its mutants by cryo-electron microscopy with and without crosslinked lipid derivatives. In Project 2, we will synthesize lipid derivatives featuring the photo-crosslinking diazirine closer to the membrane interphase to reach more transiently binding proteins such as those with a PH domain. Comparative proteomic analysis of the lipid interactomes will then be used to identify proteins involved in signalling with and without receptor stimulation. In Project 3, we will use multifunctional lipid derivatives to investigate the lipid interactomes of healthy and virus-infected cells. We recently discovered that an RNA virus infection leads to massive changes in the host cell lipidome. One exciting aspect is that one group of cellular phosphoinositides featuring a particular fatty acid composition is strongly up regulated. We will measure the lipid interactomes of flavivirus- and COVID-infected cells and identify targets crucial for viral infection and replication. Hits will be validated by protein knock-down and the effect on virus infection will be studied. Our unique lipid tools will help to better understand the lipid and lipid binding components of a viral infection.", "keywords": [ "Alkynes", "Binding Proteins", "COVID-19", "Carrier Proteins", "Cell Physiology", "Cells", "Chemistry", "Cryoelectron Microscopy", "Diazomethane", "Exhibits", "Fatty Acids", "Flavivirus", "Funding", "Glycerophospholipids", "Interphase", "Light", "Lipid Binding", "Lipids", "Location", "Measures", "Membrane", "Microscopy", "Modification", "PH Domain", "Phosphatidylinositols", "Proteins", "Proteomics", "Publishing", "RNA Virus Infections", "Recombinant Proteins", "Signal Transduction", "Site", "Small Interfering RNA", "Virus", "Virus Diseases", "Virus Replication", "Work", "comparative", "crosslink", "knock-down", "lipid transport", "lipidome", "mutant", "phosphatidylinositol 3 4 5-triphosphate", "phosphatidylinositol 3 4-diphosphate", "protein purification", "receptor", "three dimensional structure", "tool" ], "approved": true } }, { "type": "Grant", "id": "15699", "attributes": { "award_id": "1R43AR084352-01A1", "title": "Use of HIF-1alpha mRNA to Promote Pedicle Flap Healing.", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)" ], "program_reference_codes": [], "program_officials": [ { "id": 32563, "first_name": "XIBIN", "last_name": "WANG", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-06-01", "end_date": "2026-05-31", "award_amount": 296256, "principal_investigator": { "id": 32564, "first_name": "John M", "last_name": "Abraham", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2604, "ror": "", "name": "ADVANCED MOLECULAR HEALIX INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "Summary/Abstract. Surgical debridement is often used when treating major wounds, and pedicle flaps are a critical component in subsequent surgical reconstructions. Distal portions of the flap require vascular perfusion for overall success of wound repair and reconstruction. Hypoxia-inducible factor-1α (HIF-1α) is an important inducible transcription factor that orchestrates and controls cellular responses to hypoxia when paired with constitutively expressed HIF-1. HIF-1α enhances cell survival in wounds by regulating the expression of over 200 genes, including many angiogenic growth factors responsible for restoration of vascular beds. By combining the concept of increasing HIF-1α in wounds to promote cell survival and revascularization, with contemporary approaches for RNA transduction pioneered in COVID vaccines, our goal is to create a novel therapeutic strategy for enhancing pedicle flap survival. Experiments that support progress toward this goal are proposed in two specific aims: Specific Aim 1A: Quantitation of HIF-1α mRNA and response genes following intradermal injection in Sprague Dawley rats. Based on encouraging preliminary results both in vitro and in vivo, we are developing new versions of our HIF-1 mRNA reagents that are designed to improve activity when delivered in vivo using a proprietary lipid nanoparticle carrier. Rat and porcine versions of our HIF-1 mRNA reagents are being developed for use in pedicle flap assays described in Aims 1B and 2. Specific Aim 1B: In vivo assessment of HIF-1α mRNA therapeutics in a Sprague Dawley rat model of pedicle flap surgery. Findings in Aim 1A will provide preliminary data on best performing reagent structures, dose, and delivery formulations to inform testing in pedicle flap assays in male and female rats. In this aim we will measure HIF-1 expression and downstream gene induction as in Aim1A and add macroscopic monitoring of wound resolution and molecular phenotyping of the wound site using quantitative PCR and immunohistochemistry. Specific Aim 2: In vivo assessment of HIF-1α mRNA therapeutics in a porcine model of pedicle flap surgery. Pigs are valuable preclinical models for testing novel wound healing strategies. The mRNA reagents and formulations that show promise in the rat pedicle flap model in Aim 1B will subsequently be tested in a porcine model of pedicle flap survival and wound healing. Surgical outcomes will be assayed as in Aim 1B to monitor potential translatability of our studies for human clinical applications.", "keywords": [ "3&apos", "Untranslated Regions", "Applications Grants", "Award", "Binding Sites", "Biological Assay", "Blood Vessels", "Breast", "COVID-19 vaccine", "Cell Survival", "Clinical", "Complex", "Coupled", "DNA", "Data", "Debridement", "Development", "Distal", "Dose", "Excision", "Failure", "Family suidae", "Female", "Formulation", "Future", "Gene Activation", "Genes", "Goals", "Grant", "Growth Factor", "HIF1A gene", "Hernia of abdominal cavity", "Histopathology", "Human", "Hypoxia", "Hypoxia Inducible Factor", "Immunohistochemistry", "In Vitro", "Infection", "Inflammation", "Injections", "Injury", "Ischemia", "Measures", "Messenger RNA", "Methods", "MicroRNAs", "Military Personnel", "Modeling", "Molecular", "Monitor", "Mutation", "Natural regeneration", "Necrosis", "Operative Surgical Procedures", "Patients", "Perfusion", "Phase", "Plastic Surgical Procedures", "Pre-Clinical Model", "Preclinical Testing", "Preparation", "Procedures", "Protocols documentation", "Pseudouridine", "RNA", "RNA vaccine", "Rattus", "Reagent", "Reconstructive Surgical Procedures", "Resolution", "Rodent Model", "Site", "Skin", "Small Business Innovation Research Grant", "Sprague-Dawley Rats", "Standardization", "Structure", "Surgical Flaps", "System", "Testing", "Therapeutic", "Toxicology", "Translational Repression", "Traumatic injury", "Variant", "cancer surgery", "clinical application", "delivery vehicle", "design", "enhancing factor", "experimental study", "gene induction", "healing", "hypoxia inducible factor 1", "improved", "in vivo", "intradermal injection", "lipid nanoparticle", "male", "molecular phenotype", "nanolipoprotein particles", "nanoparticle delivery", "next generation", "novel", "novel therapeutic intervention", "novel therapeutics", "pharmacokinetics and pharmacodynamics", "porcine model", "preclinical study", "protein degradation", "reconstruction", "repaired", "research clinical testing", "response", "restoration", "revascularization", "success", "surgery outcome", "therapeutic evaluation", "tissue oxygenation", "transcription factor", "vascular bed", "vector", "wound", "wound care", "wound healing", "wound treatment" ], "approved": true } }, { "type": "Grant", "id": "15700", "attributes": { "award_id": "3R44GM137688-02S1", "title": "REPTOR: accelerating antibody discovery and improving hits with machine learning", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of General Medical Sciences (NIGMS)" ], "program_reference_codes": [], "program_officials": [ { "id": 32565, "first_name": "GUOQIN", "last_name": "YU", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-06-01", "end_date": "2026-07-31", "award_amount": 63564, "principal_investigator": { "id": 32566, "first_name": "Natalie", "last_name": "Castellana", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1679, "ror": "", "name": "ABTERRA BIOSCIENCES, INC.", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Antibody therapeutics are becoming increasingly important across a broad range of indications, yet their development requires discovery from a variety of difficult sources. Traditional technologies are over four decades old, while newer single-cell approaches for mining survivors are gaining traction in the wake of the SARS-Cov2 pandemic. However, all mainstream discovery approaches significantly limit the sampling of the in-vivo antibody immune response, thereby potentially missing important therapeutic candidates. Approaches to better deconvolute the antibody response with high-throughput sequencing technologies have begun to be applied for research uses. However, using these large-scale data to directly perform antibody discovery has remained elusive. We aim to develop software to streamline the incorporation of high-throughput sequencing into the three mainstream discovery approaches, thereby reducing time and increasing discovery success rate. These software-enabled enhancements will cover high-throughput sequencing for hybridoma discovery, enhanced enrichment analysis for display methods, and simplified workflow analysis for popular single-cell methods. The same type of repertoire sequencing can then be used in a different context to improve candidate antibodies by leveraging the natural improvements the host individual’s immune system has already discovered. This expansion of existing candidates is enabled by the deep sequencing of antibody repertoires using next-generation sequencing technology that provides a window into the natural antibody evolution and optimization. These newly deep repertoires are able to be exploited by novel algorithms for analyzing the large antibody families produced, as well as advances in deep learning that enable large amounts of unlabeled data to be synthesized and used for model training to search both across antibody families for similarities, as well as within those families.", "keywords": [ "Acceleration", "Algorithms", "Antibodies", "Antibody Repertoire", "Antibody Response", "COVID-19 pandemic", "Cells", "Computer software", "Data", "Development", "Evolution", "Family", "High-Throughput Nucleotide Sequencing", "Hybridomas", "Immune response", "Immune system", "Individual", "Machine Learning", "Mainstreaming", "Methods", "Mining", "Modeling", "Pharmaceutical Preparations", "Population", "Research", "Sampling", "Source", "Survivors", "Technology", "Therapeutic antibodies", "Time", "Traction", "Training", "deep learning", "deep learning model", "deep sequencing", "improved", "in vivo", "large scale data", "natural antibodies", "next generation sequencing", "novel", "novel therapeutics", "software development", "success", "therapeutic candidate" ], "approved": true } }, { "type": "Grant", "id": "15701", "attributes": { "award_id": "1U54AI191253-01", "title": "Center for Multiscale Immune Systems Modeling", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 32567, "first_name": "MEGHAN ANN", "last_name": "HARTWICK", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-06-13", "end_date": "2030-05-31", "award_amount": 4874388, "principal_investigator": { "id": 32568, "first_name": "Cliburn C", "last_name": "Chan", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 20611, "first_name": "Roger Keith", "last_name": "Reeves", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 246, "ror": "https://ror.org/00py81415", "name": "Duke University", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true } ] } ], "awardee_organization": { "id": 246, "ror": "https://ror.org/00py81415", "name": "Duke University", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true }, "abstract": "The Center of Excellence (CoE) is a research initiative that brings together experts from various fields to develop innovative solutions for multi-scale modeling in infectious and immune-mediated disease (IID). The CoE consists of the: Administrative Core (AC), Community Development and Education Core (CDEC), Model and Data Sharing Core (MDSC), and three Research Projects (RP). Each component plays a crucial role. The AC serves as a central hub, connecting various entities, and plays a critical role in pivoting CoE resources during disease outbreaks. It administers the Opportunities Fund, supporting proposals from investigators across NIAID- sponsored modeling groups. The CDEC will develop educational resources, build communities of practice and learning, organize research experiences for graduate students and postdoctoral fellows, and set up document sharing facilities, messaging platforms, and a centralized website to facilitate knowledge sharing. The MDSC will develop an informatics infrastructure that enables seamless integration of data and models across different scales, facilitating more accurate predictions and informed decision-making. The RPs focus on bridging models of host-virus interactions across biological scales. RP1 models humoral defense against viral pathogens, using antibody-antigen molecular dynamics at the molecule scale to understand the constraints limiting the evolution of immune repertoires at the individual scale. RP2 models the immune cell as a target of viral infection, using agent-based models of lymphoid tissue at the cell scale to inform host-pathogen dynamics at the individual scale. RP3 models the interactions between individuals and populations, using agent based models of host-pathogen interactions at the individual scale to inform stochastic epidemic models at the population scale. The research focuses on modeling a set of clinically important viruses, including HIV-1, SARS-CoV-2, Epstein Barr Virus (EBV), and others. The models can be used to study disease pathogenesis, the effect of medical interventions, and disease transmission in heterogeneous population networks. Key strengths of the proposed CoE are (1) the ability to coordinate administrative approaches and technologies for the infectious disease modeling community; (2) a collaborative environment that encourages knowledge sharing, innovation, and the development of cutting- edge solutions; (3) balanced representation of the experimental and computational communities within each Core and RP; (4) extensive experience with IID modeling, team science, education, and community development; (5) robust informatics infrastructure for model and data sharing that already hosts large-scale NIH- funded projects; (6) exceptional strengths integrating generative deep learning with computational modeling in the MDSC and RPs, and (7) the importance of the proposed research to develop more accurate IID models that can inform public health policy and decision-making. The unique strengths of the proposed CoE make it an ideal platform for advancing IID research, developing innovative solutions to complex problems, and responding during infectious disease outbreaks, epidemics and pandemics.", "keywords": [ "2019-nCoV", "Acceleration", "Address", "Antibodies", "Antibody Repertoire", "Antibody Response", "Antigens", "Artificial Intelligence enhanced", "Biological", "Biological Models", "Cells", "Clinical", "Cloud Computing", "Code", "Collaborations", "Communicable Diseases", "Communication", "Communities", "Community Developments", "Community Health Education", "Community of Practice", "Complex", "Computer Models", "Data", "Data Set", "Decision Making", "Dedications", "Development", "Disease", "Disease Outbreaks", "Education", "Educational workshop", "Emergency Situation", "Ensure", "Epidemic", "Escape Mutant", "Event", "Evolution", "Fostering", "Funding", "Funding Opportunities", "Goals", "Grant", "HIV-1", "Heterogeneity", "Human Herpesvirus 4", "Immune", "Immune system", "Immunological Models", "Individual", "Infection", "Information Systems", "Infrastructure", "Intervention", "Knowledge", "Leadership", "Learning", "Licensing", "Link", "Lymphoid Tissue", "Mediating", "Medical", "Mentors", "Metadata", "Modeling", "National Institute of Allergy and Infectious Disease", "Organism", "Outcome", "Pathogenesis", "Play", "Policies", "Policy Making", "Population", "Population Heterogeneity", "Positioning Attribute", "Postdoctoral Fellow", "Printing", "Public Health", "Publications", "Reproducibility", "Research", "Research Personnel", "Research Project Grants", "Resources", "Retrieval", "Role", "Running", "Science", "Scientific Advances and Accomplishments", "Services", "Strategic Planning", "Students", "System", "Technology", "Therapeutic Intervention", "Training", "Training Programs", "United States National Institutes of Health", "Viral", "Virus", "Virus Diseases", "Virus-Cell Membrane Interaction", "career", "collaborative environment", "community building", "computational platform", "computer framework", "data infrastructure", "data integration", "data modeling", "data resource", "data sharing", "deep learning", "design", "disease model", "disease transmission", "education resources", "experience", "experimental study", "graduate student", "higher education", "immunological intervention", "in silico", "infectious disease model", "informatics infrastructure", "innovation", "interdisciplinary approach", "learning community", "meetings", "molecular dynamics", "multi-scale modeling", "new epidemic", "novel", "open source", "outbreak preparedness", "outbreak response", "pandem" ], "approved": true } }, { "type": "Grant", "id": "15702", "attributes": { "award_id": "1R21TR005645-01", "title": "Accelerating the translation of oligonucleotide therapeutics by enhancing delivery", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Center for Advancing Translational Sciences (NCATS)" ], "program_reference_codes": [], "program_officials": [ { "id": 32569, "first_name": "KIHWA", "last_name": "KANG", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-06-16", "end_date": "2027-06-15", "award_amount": 419398, "principal_investigator": { "id": 32570, "first_name": "Aimee L", "last_name": "Edinger", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 971, "ror": "", "name": "UNIVERSITY OF CALIFORNIA-IRVINE", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Oligonucleotide therapeutics (ONTs) are poised to ignite a paradigm shift in what constitutes a “treatable” human disease. The FDA approval of life-changing ONTs like Spinraza (Ionis’ ASO therapy for spinal muscular atrophy), Onpattro (Alnylam’s siRNA therapy for hATTR amyloidosis), and the mRNA-based COVID-19 vaccines from Pfizer and Moderna that saved millions of lives demonstrate the profound potential impact ONTs can have on “undruggable” diseases. CRISPR-based editing strategies are now entering the clinic, with lipid nanoparticle-mediated delivery of mRNA encoding Cas9 variants offering an alternative to problematic viral vectors. Suppressor tRNAs that read through premature stop codons to restore proteins that were “lost in translation” are moving towards the clinic. Each of these ONTs faces a shared barrier to broad clinical translation: biological membranes. The large size (5-35 kD) and charged backbone of ONTs severely limits their ability to cross the plasma membrane. Even if the plasma membrane is crossed by promoting the endocytosis of the ONT, the endosomal membrane remains a highly effective barrier that prevents ONTs from reaching their targets in the cytosol and nucleus. Estimates are that only 1-3% of the ONT delivered to a patient reaches its target - the delivery stats are dismal for naked, ligand-conjugated, and LNP-encased ONTs. ONTs tend to accumulate in the liver, and most FDA-approved ONTs that are delivered systemically have liver targets. ONT conjugation to GalNAc, the ligand for the asialoglycoprotein receptor expressed on hepatocytes, improves delivery 30-fold. Other approved agents rely on local delivery to increase ONT exposure to a level sufficient to provide clinical value. However, not all tissues are suited for local delivery, many cell types with these tissues remain inaccessible to ONTs, and local delivery risks infection or damage to the target organ. There is thus a critical unmet need for strategies that improve the delivery of systemically administered ONTs to extrahepatic tissues. Until this need is met, a revolution in medical practice ushered in by nucleotide-based therapies will remain a dream unrealized. This proposal seeks a small molecule solution to the delivery problem. This strategy would be effective for multiple ONT platforms and disease agnostic. By drilling down on rigorous target validation from the outset, we hope to initiate a successful drug development program that takes the most direct path to the clinic. Our lead compounds diverge from status quo potentiators in that they dramatically increase ONT activity without causing endosomal damage, an effective, but prohibitively toxic, mode of action. The expected results would provide a solid foundation for funding a successful lead optimization program supported by target engagement assays and highlight the diseases most likely to rapidly realize the benefits of this approach.", "keywords": [ "Acceleration", "Amyloidosis", "Antibodies", "Antisense Oligonucleotide Therapy", "Antisense Oligonucleotides", "Asialoglycoprotein Receptor", "Back", "Biological", "Biological Assay", "COVID-19 pandemic", "COVID-19 vaccine", "Cardiovascular Diseases", "Cell Nucleus", "Cell membrane", "Cells", "Cellular Membrane", "Charge", "Chemicals", "Child", "Childhood", "Climacteric", "Clinic", "Clinical", "Clustered Regularly Interspaced Short Palindromic Repeats", "Cystic Fibrosis", "Cytoplasm", "Cytosol", "Data", "Diabetes Mellitus", "Disease", "Dreams", "Effectiveness", "Encapsulated", "Endocytosis", "Endosomes", "Evaluation", "Exposure to", "Extrahepatic", "FDA approved", "Face", "Familial Amyloid Neuropathies", "Floods", "Foundations", "Funding", "Goals", "Government", "Hepatic Tissue", "Hepatocyte", "Human", "Individual", "Intramuscular Injections", "Ion Channel", "Kidney Diseases", "Lead", "Ligands", "Liver", "Mediating", "Medical", "Medicine", "Membrane", "Messenger RNA", "Methods", "Mus", "Muscular Dystrophies", "Neurodegenerative Disorders", "Nonsense Codon", "Nucleotides", "Obesity", "Organ", "Outcomes Research", "Patients", "Persons", "Pfizer-BioNTech COVID-19 vaccine", "Program Development", "Protein Isoforms", "Proteins", "RNA vaccine", "Reporting", "Research", "Safety", "Small Interfering RNA", "Solid", "Spinal Muscular Atrophy", "Testing", "Therapeutic", "Thick", "Tissues", "Toxic effect", "Transfer RNA", "Translations", "Validation", "Variant", "Vertebral column", "Viral Vector", "Work", "base editing", "cell type", "clinical development", "clinical translation", "drug development", "endosome membrane", "gene-editing approach", "human disease", "improved", "in vivo", "infection risk", "inhibitor", "innovation", "knock-down", "lead optimization", "lipid nanoparticle", "mRNA delivery", "next generation", "oligonucleotide delivery", "oligonucleotide therapeutics", "preclinical development", "prevent", "programs", "receptor mediated endocytosis", "small molecule", "small molecule libraries", "targeted delivery", "therapeutic siRNA", "trafficking", "virtual" ], "approved": true } }, { "type": "Grant", "id": "15703", "attributes": { "award_id": "1R13DC022794-01", "title": "The 10th International Symposium on Middle Ear Mechanics in Research and Otology (MEMRO 2025)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Deafness and Other Communication Disorders (NIDCD)" ], "program_reference_codes": [], "program_officials": [ { "id": 32571, "first_name": "BRACIE", "last_name": "WATSON", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-06-01", "end_date": "2026-05-31", "award_amount": 51000, "principal_investigator": { "id": 32572, "first_name": "STEPHEN", "last_name": "CASS", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 32573, "first_name": "Nathaniel Tussing", "last_name": "Greene", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 32574, "first_name": "Daniel J", "last_name": "Tollin", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 784, "ror": "https://ror.org/02hh7en24", "name": "University of Colorado Denver", "address": "", "city": "", "state": "CO", "zip": "", "country": "United States", "approved": true }, "abstract": "We are seeking partial support through this proposal to cover the expenses for the 10th International Meeting of the Middle Ear Mechanics in Research and Otology (MEMRO) 2025 conference, scheduled for June 2025 at the KU Leuven, in Belgium. In alignment with the objectives established at the inaugural MEMRO meeting in 1996, the purpose of this triennial event is to bring together experts in middle ear science and engineering with clinical otologists to facilitate an exchange of knowledge and ideas between these typically independent groups. Previous MEMRO meetings in Shanghai (2018) and Denmark (2015) each attracted approximately 200 participants from over 20 countries. The 2022 meeting had slightly fewer participants since scientists from many countries, including China, Japan, Australia, and others, that would normally attend the MEMRO meetings were still precluded from travel due to COVID restrictions. We expect the 10th edition to have a higher attendance. The 2025 meeting aims to continue promoting the free exchange of ideas between basic and clinical scientists and to establish a framework for innovative collaborative efforts to enhance our understanding of middle ear function, dysfunction, and repair. A primary goal of this meeting is to increase the diversity of attendees, with a particular focus on engaging otology residents and faculty by hosting a hands-on workshop on methods and technologies the day prior to the formal conference. Also many efforts have been made to increase the presence of underrepresented countries. We have promoted the conference on multiple occasions on other world conferences. We have representatives from all continents in the scientific committee. The 2025 MEMRO meeting is being organized by KU Leuven, Belgium's largest and highest-ranked university and is an excellent center for education, research and Innovation. Leuven is a vibrant city only 15 minutes by train from Brussels Airport allowing easy travel, and is rich in art, history, and architecture, offering attendees ample opportunities to experience this dynamic international city.", "keywords": [ "Acoustics", "Architecture", "Australia", "Basic Science", "Belgium", "Biology", "Biomechanics", "Biophysics", "COVID-19", "China", "Cities", "Clinical", "Cochlear Implants", "Collaborations", "Communication", "Conductive hearing loss", "Country", "Denmark", "Diagnosis", "Disabling", "Disadvantaged", "Disease", "Ear", "Economics", "Education", "Educational workshop", "Emerging Technologies", "Employment", "Engineering", "Event", "External auditory canal", "Faculty", "Fostering", "Functional disorder", "Goals", "Hearing", "Hearing Aids", "Implant", "Individual", "International", "Japan", "Knowledge", "Labyrinth", "Lead", "Mechanics", "Medical", "Methods", "Operative Surgical Procedures", "Otolaryngologist", "Otology", "Outcome", "Participant", "Pathogenesis", "Pathologic", "Pathology", "Process", "Recording of previous events", "Research", "Research Personnel", "Schedule", "Science", "Scientist", "Sensory", "Social isolation", "Stimulus", "Structure", "Students", "Surgeon", "Technology", "Training", "Travel", "Tympanic membrane", "Universities", "Vision", "World Health Organization", "experience", "hearing impairment", "improved", "innovation", "interest", "meetings", "microphone", "middle ear", "middle ear disorder", "multidisciplinary", "neural", "repaired", "symposium", "technological innovation" ], "approved": true } }, { "type": "Grant", "id": "15705", "attributes": { "award_id": "1R24AI186970-01A1", "title": "Enhancing the utility of deer mice as an infectious disease model", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 32576, "first_name": "NADINE", "last_name": "BOWDEN", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-06-01", "end_date": "2030-05-31", "award_amount": 466725, "principal_investigator": { "id": 32577, "first_name": "Ioulia", "last_name": "Chatzistamou", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 23713, "first_name": "Kiesha", "last_name": "Wilson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 930, "ror": "", "name": "UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA", "address": "", "city": "", "state": "SC", "zip": "", "country": "United States", "approved": true } ] }, { "id": 31996, "first_name": "Hippokratis", "last_name": "Kiaris", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 930, "ror": "", "name": "UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA", "address": "", "city": "", "state": "SC", "zip": "", "country": "United States", "approved": true }, "abstract": "Deer mice (genus Peromyscus) are the most abundant mammals in North America. In biomedical research, their most prominent use is in the field of infectious diseases, because they are the natural reservoir of infectious agents such as Borrelia burgdorferi which causes Lyme disease, for Hantaviruses, Sin Nombre Virus, and SARS-CoV-2 that caused the COVID-19 pandemic. The University of South Carolina operates, for more than 40 years, the Peromyscus Genetic Stock Center (PGSC) that is charged with the mission of maintaining different stocks of Peromyscus, supplying them to outside investigators and exploiting deer mouse- related research. The present proposal addresses 3 major unmet needs of the Peromyscus community of researchers that impede the use of deer mice as a model and are related to the poor breeding program that does not enable rapid availability if deer mice to users, the lack of Peromyscus-specific antibodies, and the lack of readily access to breeding records for pedigree analyses. Here, we request funds to enhance the utility of deer mice as a model of relevance to NIAID’s interests by (1) strengthening the breeding capacities of the PGSC, (2) by developing specialized immunological reagents such as Peromyscus-specific antibodies, and (3) by curating our electronic databases and rendering them easily accessible to outside users. Plans for the project’s sustainability have been developed, and it is anticipated that upon completion it will be supported fully by the income generated.", "keywords": [ "2019-nCoV", "Address", "Animal Model", "Animals", "Antibodies", "Antigens", "Back", "Behavior", "Biomedical Research", "Books", "Borrelia burgdorferi", "Breeding", "COVID-19 pandemic", "Charge", "Communicable Diseases", "Communities", "Consultations", "Databases", "Deer Mouse", "Ecology", "Electronics", "Evolution", "Funding", "Generations", "Genetic", "Genetic Enhancement", "Genetic Variation", "Genomics", "Goals", "Hantavirus", "Human Resources", "Immune response", "Immune system", "Immunologics", "Inbreeding", "Income", "Infectious Agent", "Infectious Diseases Research", "Inflammation", "Lyme Disease", "Maintenance", "Mammalian Cell", "Mammals", "Manuals", "Mental Depression", "Metabolism", "Mission", "Modeling", "Monitor", "Monoclonal Antibodies", "Mus", "National Institute of Allergy and Infectious Disease", "North America", "Operations Research", "Pathology", "Peromyscus", "Plasmids", "Predisposition", "Production", "Reagent", "Records", "Request for Proposals", "Research", "Research Contracts", "Research Personnel", "Resources", "Sin Nombre virus", "South Carolina", "Surveys", "Testing", "Time", "United States National Institutes of Health", "Universities", "Validation", "Work", "experimental study", "genetic pedigree", "genome resource", "genomic tools", "infectious disease model", "interest", "model organism", "programs", "repository", "tool", "user-friendly" ], "approved": true } }, { "type": "Grant", "id": "15706", "attributes": { "award_id": "1K23GM159013-01", "title": "Targeting Immune Dysregulated Endotypes in Sepsis (TIDES)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of General Medical Sciences (NIGMS)" ], "program_reference_codes": [], "program_officials": [ { "id": 24133, "first_name": "SYDELLA ANNE", "last_name": "BLATCH", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-06-01", "end_date": "2028-05-31", "award_amount": 179475, "principal_investigator": { "id": 32578, "first_name": "Robert B", "last_name": "Lindell", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1073, "ror": "", "name": "CHILDREN'S HOSP OF PHILADELPHIA", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "/ ABSTRACT Pediatric sepsis is the leading cause of death of hospitalized children worldwide. While sepsis is defined as life-threatening organ dysfunction that develops in the setting of immune dysregulation, optimal management of immune dysregulation in pediatric sepsis is a fundamental knowledge gap. A successful precision medicine approach to pediatric sepsis requires that we understand the molecular events that cause organ failure, which of these events are potentially reversible, and how to identify this reversible patient pathobiology in real-time. We recently identified features of cellular immune dysregulation in children with sepsis and used proteomics to define three molecular subphenotypes which predict the severity of organ failure and mortality. Reproducible, validated molecular sepsis subphenotypes are viable candidates for translation to clinical trials, as models based on clinical data and plasma proteins could be used to identify “treatable traits” in real-time for both prognostic and predictive enrichment. Our preliminary data also identifies a pathologic and potentially reversible role for STAT3 hyperactivation in our most severe sepsis subphenotype. The IL-6/JAK/STAT3 signaling pathway is a canonical inflammatory pathway associated with capillary leak, endothelial dysfunction, emergency granulopoiesis, and lymphocyte dysregulation. Selective and non-selective JAK inhibitors have been used clinically to treat COVID-19 ARDS and pediatric hemophagocytic lymphohistiocytosis (HLH). It is not known if JAK inhibition can reverse immune dysregulation in sepsis, despite its related pathobiology. We propose to address these current knowledge gaps by defining and validating molecular subphenotype that predicts sepsis severity and testing the reversibility of T cell STAT3 hyperactivation. The overall objectives of this application are to define and prospectively evaluate a model to identify prognostic molecular sepsis subphenotypes (Aim 1) and to determine the impact of ex vivo JAK/STAT inhibition to reduce immune dysregulation in pediatric patients with sepsis (Aim 2). My central hypothesis is that immune dysregulation in pediatric sepsis can be identified in the plasma proteome and reversed with targeted immunomodulation. By validating a model to prospectively identify prognostic molecular sepsis subphenotypes and determining the impact of JAK/STAT inhibition on immune dysregulation, this study will support a precision approach to immunomodulation in pediatric patients with sepsis. My long-term goal is to design precision approaches to immunomodulation in critically ill children as a translational critical care physician-scientist trained in computational human immunology. I am optimally situated to perform these studies given my background as a clinician, my experience in prospective cohort development and proteomic subphenotyping, and the strong mentorship and supportive environment at CHOP/UPenn. The K23 award will provide new skills in translational research and computational analysis, facilitating my development as an independent investigator with expertise in translational human immunology.", "keywords": [ "Address", "Blood capillaries", "Blood specimen", "COVID-19 patient", "COVID-19 treatment", "COVID-19/ARDS", "Cause of Death", "Childhood", "Clinical", "Clinical Data", "Clinical Trials", "Computer Analysis", "Computing Methodologies", "Critical Care", "Critically ill children", "Cryopreservation", "Data", "Data Set", "Development", "Dimerization", "Emergency Situation", "Enrollment", "Event", "Factor Analysis", "Flow Cytometry", "Functional disorder", "Genetic Transcription", "Goals", "Granulopoiesis", "Hemophagocytic Lymphohistiocytoses", "Hospitalized Child", "Human", "IL6ST gene", "Immune", "Immune Targeting", "Immunoassay", "Immunology", "Inflammatory", "Interleukin-6", "JAK1 gene", "Knowledge", "Life", "Lymphocyte", "Machine Learning", "Mediating", "Mentored Clinical Scientist Development Program", "Mentored Patient-Oriented Research Career Development Award", "Mentorship", "Modeling", "Molecular", "Multiomic Data", "Multiple Organ Failure", "Organ", "Organ failure", "Pathologic", "Pathway interactions", "Patients", "Performance", "Peripheral Blood Mononuclear Cell", "Phenotype", "Phosphorylation", "Physicians", "Plasma", "Plasma Proteins", "Positioning Attribute", "Production", "Prospective cohort", "Protein Tyrosine Kinase", "Proteins", "Proteome", "Proteomics", "Recovery", "Reproducibility", "Research Personnel", "Role", "STAT3 gene", "Sampling", "Scientist", "Sepsis", "Severities", "Signal Transduction", "Stat3 Signaling Pathway", "System", "T-Lymphocyte", "TYK2", "Testing", "Therapeutic Effect", "Time", "Training", "Translational Research", "Translations", "Validation", "Whole Blood", "cohort", "cytokine", "design", "endothelial dysfunction", "experience", "immunoregulation", "improved", "inhibitor", "learning strategy", "mortality", "multiple omics", "pediatric patients", "pediatric sepsis", "personalized approach", "precision medicine", "predict clinical outcome", "prognostic", "prospective", "randomized trial", "septic patients", "severe sepsis", "single-cell RNA sequencing", "skills", "supportive environment", "trait", "transcription factor" ], "approved": true } }, { "type": "Grant", "id": "15709", "attributes": { "award_id": "1R21DE033795-01A1", "title": "SARS-CoV-2 tropism and immunomodulation in salivary gland", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Dental and Craniofacial Research (NIDCR)" ], "program_reference_codes": [], "program_officials": [ { "id": 32580, "first_name": "TAMARA L", "last_name": "MCNEALY", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-06-17", "end_date": "2027-06-16", "award_amount": 401500, "principal_investigator": { "id": 32581, "first_name": "Taichiro", "last_name": "Nonaka", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 835, "ror": "", "name": "LOUISIANA STATE UNIV HSC SHREVEPORT", "address": "", "city": "", "state": "LA", "zip": "", "country": "United States", "approved": true }, "abstract": "SARS-CoV-2 has been detected in a variety of human tissues, including the salivary gland. While its behavior in the respiratory tract has been widely studied, relatively little is known about how this virus interacts with oral tissues and the local immune environment. The salivary gland may serve as a unique site of viral presence and immunological modulation, particularly through pathways involving non-classical major histocompatibility complex (MHC) class I molecules. This project aims to investigate fundamental aspects of the innate immune response to SARS-CoV-2 within the salivary gland, with a focus on the molecular interactions between virus- or host-derived peptides and components of the mucosal immune system. In particular, we will explore how antigen presentation mechanisms may shape or reflect local immune activity in this tissue. Identifying such mechanisms will advance our understanding of tissue-specific immune regulation and viral tropism. The proposed research is designed to clarify basic molecular and cellular processes that underlie host-pathogen interactions in the oral cavity. By studying immunological dynamics in the salivary gland, this work will contribute to a framework for understanding mucosal immunity and may reveal foundational principles of immune surveillance in non-respiratory tissues.", "keywords": [ "2019-nCoV", "Acute", "Adult", "Affinity", "Antigen Presentation", "Behavior", "Binding", "Biological Assay", "Biology", "COVID-19", "COVID-19 pandemic", "COVID-19 patient", "Cell Physiology", "Cells", "Centers for Disease Control and Prevention (U.S.)", "Child", "Chimeric Proteins", "Complex", "Detection", "Disease", "Environment", "Family", "Flow Cytometry", "Frequencies", "Functional disorder", "Gingivitis", "Glycoproteins", "HLA Antigens", "Human", "Immune", "Immunologic Surveillance", "Immunologics", "Immunotherapeutic agent", "Impairment", "In Vitro", "Infection", "Innate Immune Response", "Investigation", "KLRD1 gene", "Knowledge", "Ligands", "Lingual tonsil", "Long COVID", "Major Histocompatibility Complex", "Metalloproteases", "Molecular", "Mouth Diseases", "Mucosal Immune System", "Mucosal Immunity", "NK Cell Activation", "Natural Killer Cells", "Nature", "Oral", "Oral Ulcer", "Oral cavity", "Oropharyngeal", "Outcome", "Palatine Tonsil", "Pathway interactions", "Patients", "Peptides", "Persons", "Phase", "Population", "Property", "Reporting", "Research", "Respiratory Disease", "Respiratory System", "Risk Reduction", "Role", "SARS-CoV-2 infection", "Saliva", "Salivary", "Salivary Glands", "Sampling", "Shapes", "Site", "Source", "Stains", "Systemic disease", "Taste Perception", "Testing", "Tissues", "Tonsil", "Tropism", "Upregulation", "Viral", "Virus", "Work", "Xerostomia", "betacoronavirus", "design", "human tissue", "immunoregulation", "novel", "novel therapeutic intervention", "novel virus", "oral immunology", "oral tissue", "pandemic disease", "pathogen", "receptor", "response", "severe COVID-19", "transmission process", "viral RNA", "viral transmission" ], "approved": true } } ], "meta": { "pagination": { "page": 1404, "pages": 1424, "count": 14236 } } }